“The information presented at the tumor boards is timely, relevant and difficult for the community oncologist to acquire in other ways.” - Sarah Ketchum, M.D., MCGI Clinician
“The information presented at the tumor boards is timely, relevant and difficult for the community oncologist to acquire in other ways.” - Sarah Ketchum, M.D., MCGI Clinician
The MCGI Genomic Tumor Board (GTB) Series is a set of virtual, case-based meetings. Each session brings together oncologists, expert advisors, genetic counselors and medical science liaisons from the respective testing companies to review biomarker test results. The discussions focus on potential treatment options for the patient and supporting the clinicians in applying precision medicine in practice.
Designed to address one of the biggest challenges in cancer care, the interpretation of complex genomic data, GTBs provide an efficient, collaborative forum for translating results into actionable care decisions. Sessions are held virtually for convenient access, CME-eligible and open to clinicians interested in presenting de-identified cases. To learn more, contact [email protected].
All sessions convene via video-teleconference (VTC) in U.S. Eastern Time.
Accredited CME in cancer genomics for clinicians. Learn how genomic insights can be applied to support informed, evidence-based patient care.
CME evaluations are sent electronically at the end of the GTB series to everyone who signed in. After submitting the evaluation, physicians receive credit for the sessions they attended. Non-physician attendees do not receive CME credit but may request a certificate of participation.
Clinicians who would like to attend GTB sessions can contact [email protected] to be added to the invitation list.
Alanna Church, M.D.
Pathologist
DANA-FARBER/BOSTON CHILDREN'S CANCER AND BLOOD DISORDERS CENTER
Rachel Elsey, Pharm.D., BCOP
Pharmacist
AVERA CANCER INSTITUTE
Suzanne Forrest, M.D.
Medical Oncologist
DANA-FARBER/BOSTON CHILDREN'S CANCER AND BLOOD DISORDERS CENTER
Charlie Gourley, Ph.D.
Gynecologic Oncologist
UNIVERSITY OF EDINBURGH
J. Kevin Hicks, Pharm.D., Ph.D.
Gynecologic Oncologist
MOFFITT CANCER CENTER
Douglas B. Johnson, M.D., MSCI
Medical Oncologist
VANDERBILT UNIVERSITY MEDICAL CENTER
Todd Knepper, Pharm.D.
Pharmacist
MOFFITT CANCER CENTER
Ben Kong, Pharm.D.
Pharmacist
OREGON HEALTH & SCIENCE UNIVERSITY
Sebastian Lange
Gastrointestinal Oncologist
TECHNICAL UNIVERSITY OF MUNICH
Ryan Nguyen, D.O.
Medical Oncologist
UNIVERSITY OF ILLINOIS CANCER CENTER
Jai Patel, Pharm.D.
Pharmacogenomics Researcher
ATRIUM HEALTH WAKE FOREST BAPTIST COMPREHENSIVE CANCER CENTER
Ryan Sullivan, M.D.
Medical Oncologist
MASSACHUSETTS GENERAL HOSPITAL
David Thomas, MBBS, Ph.D.
Medical Oncologist
UNIVERSITY OF NEW SOUTH WALES
Christine M. Walko, Pharm.D.
Pharmacist
MOFFITT CANCER CENTER
Ben Westphalen, M.D.
Medical Oncologist
COMPREHENSIVE CANCER CENTRE MUNICH
Qian Wu, M.D.
Pathologist
UNIVERSITY OF CONNECTICUT
Oladapo Yeku, M.D., Ph.D.
Medical Oncologist
MASSACHUSETTS GENERAL HOSPITAL
Strengthen your understanding of a patient's genetic construct to make more informed decisions on treatment, ultimately leading to enhanced outcomes and prognosis.
Utilize the JAX APML to advance your research and keep driving towards tomorrow's discovery.